Reprogramming stem cells in regenerative medicine.

Smart medicine Pub Date : 2022-12-25 eCollection Date: 2022-12-01 DOI:10.1002/SMMD.20220005
Jiayi Mao, Qimanguli Saiding, Shutong Qian, Zhimo Liu, Binfan Zhao, Qiuyu Zhao, Bolun Lu, Xiyuan Mao, Liucheng Zhang, Yuguang Zhang, Xiaoming Sun, Wenguo Cui
{"title":"Reprogramming stem cells in regenerative medicine.","authors":"Jiayi Mao, Qimanguli Saiding, Shutong Qian, Zhimo Liu, Binfan Zhao, Qiuyu Zhao, Bolun Lu, Xiyuan Mao, Liucheng Zhang, Yuguang Zhang, Xiaoming Sun, Wenguo Cui","doi":"10.1002/SMMD.20220005","DOIUrl":null,"url":null,"abstract":"<p><p>Induced pluripotent stem cells (iPSCs) that are generated from adult somatic cells are induced to express genes that make them pluripotent through reprogramming techniques. With their unlimited proliferative capacity and multifaceted differentiation potential and circumventing the ethical problems encountered in the application of embryonic stem cells (ESC), iPSCs have a broad application in the fields of cell therapy, drug screening, and disease models and may open up new possibilities for regenerative medicine to treat diseases in the future. In this review, we begin with different reprogramming cell technologies to obtain iPSCs, including biotechnological, chemical, and physical modulation techniques, and present their respective strengths, and limitations, as well as the recent progress of research. Secondly, we review recent research advances in iPSC reprogramming-based regenerative therapies. iPSCs are now widely used to study various clinical diseases of hair follicle defects, myocardial infarction, neurological disorders, liver diseases, and spinal cord injuries. This review focuses on the translational clinical research around iPSCs as well as their potential for growth in the medical field. Finally, we summarize the overall review and look at the potential future of iPSCs in the field of cell therapy as well as tissue regeneration engineering and possible problems. We believe that the advancing iPSC research will help drive long-awaited breakthroughs in cellular therapy.</p>","PeriodicalId":74816,"journal":{"name":"Smart medicine","volume":" ","pages":"e20220005"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11235200/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Smart medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/SMMD.20220005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Induced pluripotent stem cells (iPSCs) that are generated from adult somatic cells are induced to express genes that make them pluripotent through reprogramming techniques. With their unlimited proliferative capacity and multifaceted differentiation potential and circumventing the ethical problems encountered in the application of embryonic stem cells (ESC), iPSCs have a broad application in the fields of cell therapy, drug screening, and disease models and may open up new possibilities for regenerative medicine to treat diseases in the future. In this review, we begin with different reprogramming cell technologies to obtain iPSCs, including biotechnological, chemical, and physical modulation techniques, and present their respective strengths, and limitations, as well as the recent progress of research. Secondly, we review recent research advances in iPSC reprogramming-based regenerative therapies. iPSCs are now widely used to study various clinical diseases of hair follicle defects, myocardial infarction, neurological disorders, liver diseases, and spinal cord injuries. This review focuses on the translational clinical research around iPSCs as well as their potential for growth in the medical field. Finally, we summarize the overall review and look at the potential future of iPSCs in the field of cell therapy as well as tissue regeneration engineering and possible problems. We believe that the advancing iPSC research will help drive long-awaited breakthroughs in cellular therapy.

再生医学中的干细胞再编程
诱导多能干细胞(iPSCs)是由成人体细胞通过重编程技术诱导表达使其具有多能性的基因而产生的。iPSC 具有无限的增殖能力和多方面的分化潜能,并规避了胚胎干细胞(ESC)应用中遇到的伦理问题,在细胞治疗、药物筛选和疾病模型等领域具有广泛的应用前景,并为未来再生医学治疗疾病开辟了新的可能性。在这篇综述中,我们首先介绍了获得 iPSCs 的不同重编程细胞技术,包括生物技术、化学和物理调控技术,并介绍了它们各自的优势和局限性,以及最近的研究进展。目前,iPSCs 已被广泛应用于毛囊缺损、心肌梗塞、神经系统疾病、肝脏疾病和脊髓损伤等多种临床疾病的研究。本综述重点关注围绕 iPSCs 的转化临床研究及其在医学领域的发展潜力。最后,我们对综述进行了总结,并展望了 iPSCs 在细胞疗法和组织再生工程领域的潜在前景以及可能存在的问题。我们相信,不断推进的 iPSC 研究将有助于推动细胞疗法取得期待已久的突破。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信